ORIC ORIC Pharmaceuticals, Inc.
USHealthcareAs of 2026-10-08
Why ORIC matters now
ORIC Pharmaceuticals, Inc. (ORIC) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.03 with +0.17% on the session and $1.25B in market capitalization; recent performance reads 1-month +6.52% and YTD +3.79%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-35.8M, and EPS of $-0.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -12.7%.
The latest indexable market news headline is "ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.50; recent insider activity includes Piscitelli Dominic filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.15
P/S
0.00
EV/EBITDA
-6.16
DCF Value
$0.35
FCF Yield
-12.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.3%
ROA
-31.0%
ROIC
-35.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-35.8M | $-0.34 |
| Q4 2025 | $0.00 | $-30.5M | $-0.30 |
| FY 2025 | $0.00 | $-129.5M | $-1.47 |
| Q3 2025 | $0.00 | $-32.6M | $-0.33 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$19.25
Target (Median)
$18.50
Target Range
$15.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.06
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.